Program
PRT13722
A development code.
Its studies are mostly in Breast Neoplasms, led by Prelude Therapeutics.
Furthest: phase 1, since Oct 15, 20261 company-led study, 1 open or runningNext primary completion: Oct 31, 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Prelude Therapeutics | 11 open or running | phase 1since Oct 15, 2026 | Oct 15, 2026 | Oct 31, 2028phase 1 · NCT07905001 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 15, 2026First study: phase 1 study in Breast NeoplasmsFirst studyNCT07905001 · 242 planned · United States
Ahead
- Oct 31, 2028Primary completion: phase 1 study in Breast NeoplasmsNCT07905001
TargetBeta
KAT6A →read by rule
“A Phase 1/1b, First-in-Human, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of PRT13722, a KAT6A Protein Degrader, as Monotherapy and in Combination With Endocrine and Targeted Therapy in Adults With Locally Advanced…”study text, by rule · the study
Other programs on KAT6A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| prifetrastat | Pfizer | phase 3 | 10 |
| KAT6A/B Inhibitor BG-75202rule | BeOne Medicines | phase 1 | 2 |
| HRS-2189 | Jiangsu HengRui Medicine | phase 1 | 2 |
| KAT6 Inhibitor OP-3136rule | olema-pharmaceuticals-inc | phase 1 | 1 |
| KAT6/KAT7 Inhibitor PF-08032562rule | Pfizer | phase 1 | 1 |
| KAT6/KAT7 Inhibitor IDE574rule | ideaya-biosciences | phase 1 | 1 |
| HLX97 | Fosun Pharma | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07905001Breast Neoplasms · United States | 1 | Recruiting | Oct 31, 2028 | 242 |
How it is read
Names in the registry
- “PRT13722”, 1 entry
Codes read as this program: PRT13722.
Conditions, from the studies’ own filings
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.